Latest & greatest articles for montelukast

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on montelukast or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on montelukast and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for montelukast

1. Montelukast (Singulair): reminder of the risk of neuropsychiatric reactions

Montelukast (Singulair): reminder of the risk of neuropsychiatric reactions Montelukast (Singulair): reminder of the risk of neuropsychiatric reactions - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Montelukast (...) (Singulair): reminder of the risk of neuropsychiatric reactions Prescribers should be alert for neuropsychiatric reactions in patients taking montelukast and carefully consider the benefits and risks of continuing treatment if they occur. Published 19 September 2019 From: Therapeutic area: , , Contents Advice for healthcare professionals: be alert for neuropsychiatric reactions in patients taking montelukast; events have been reported in adults, adolescents, and children (see list of reported events

2019 MHRA Drug Safety Update

2. Montelukast

Montelukast Top results for montelukast - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for montelukast The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

3. Montelukast versus inhaled mometasone for treatment of otitis media with effusion in children: A randomized controlled trial Full Text available with Trip Pro

Montelukast versus inhaled mometasone for treatment of otitis media with effusion in children: A randomized controlled trial Otitis media is one of the most common infections among children and is a complication in about 30% of common colds. The most common complication of acute otitis media is otitis media with effusion. Some studies have reported the effects of montelukast and mometasone nasal spray in treatment of otitis media with effusion. However, current information is inadequate (...) in this issue.To compare the effectiveness of montelukast and mometasone nasal spray in treatment of otitis media with effusion in children attending Koodakan hospital in Bandar Abbas, Iran.This randomized controlled trial was done on 2- to 6-year-old children attending Koodakan Hospital in Bandar Abbas, southern Iran, in 2014. Patients were divided into three groups of montelukast, mometasone, and control group. Audiometry was done for all patients at baseline and four weeks after treatment. Patients were

2017 Electronic physician Controlled trial quality: uncertain

4. Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma Full Text available with Trip Pro

Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma Roflumilast, a selective phosphodiesterase 4 inhibitor, has been shown to provide modest improvements in lung function in patients with mild-to-moderate asthma, but its efficacy in patients with moderate-to-severe asthma has not been assessed. We hypothesized that this drug might provide benefit if combined with montelukast, a leukotriene receptor antagonist, in patients (...) whose symptoms are uncontrolled by inhaled corticosteroids and long-acting β-agonists.We sought to examine the efficacy, safety, and mode of action of the addition of roflumilast and montelukast versus montelukast alone in patients with moderate-to-severe asthma.In a phase 2, randomized, double-blind, placebo-controlled, multiple-dose, 2-sequence, crossover study, 64 patients were randomized to receive 500 μg of roflumilast plus montelukast followed by placebo plus 10 mg of montelukast (sequence AB

2016 EvidenceUpdates Controlled trial quality: predicted high

5. Parent-determined oral montelukast therapy for preschool wheeze with stratification for arachidonate 5-lipoxygenase (ALOX5) promoter genotype: a multicentre, randomised, placebo-controlled trial Full Text available with Trip Pro

Parent-determined oral montelukast therapy for preschool wheeze with stratification for arachidonate 5-lipoxygenase (ALOX5) promoter genotype: a multicentre, randomised, placebo-controlled trial Parent-determined oral montelukast therapy for preschool wheeze with stratification for arachidonate-5-lipoxygenase (ALOX5) promoter genotype. Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested

2015 NIHR HTA programme

6. Montelukast for sleep apnea: a review of the clinical effectiveness, cost effectiveness, and guidelines

Montelukast for sleep apnea: a review of the clinical effectiveness, cost effectiveness, and guidelines Montelukast for sleep apnea: a review of the clinical effectiveness, cost effectiveness, and guidelines Montelukast for sleep apnea: a review of the clinical effectiveness, cost effectiveness, and guidelines CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation CADTH. Montelukast for sleep apnea: a review of the clinical effectiveness, cost effectiveness, and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal. 2014 Authors' conclusions One study found that montelukast improved respiratory disturbances in children with mild to moderate obstructive sleep apnea (OSA). No published trials regarding the use of montelukast in adults with OSA were identified

2014 Health Technology Assessment (HTA) Database.

7. Montelukast

Montelukast USE OF MONTELUKAST IN PREGNANCY 0344 892 0909 USE OF MONTELUKAST IN PREGNANCY (Date of issue: August 2015 , Version: 2.1 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Montelukast is a cysteinyl leukotriene type-1 receptor (...) antagonist licensed as an anti-asthmatic medication for patients inadequately controlled by inhaled corticosteroids or short-acting beta-agonists, and for asthmatics with exercise-induced bronchoconstriction. Although the available data are limited both by lack of power and/or formal statistical analysis in some studies, there is currently no good evidence that montelukast exposure during pregnancy increases the overall risk of congenital malformation, spontaneous abortion, intrauterine death, decreased

2014 UK Teratology Information Service

8. Randomised controlled trial: Montelukast potentially efficacious in children with non-severe obstructive sleep apnoea in the short term

Randomised controlled trial: Montelukast potentially efficacious in children with non-severe obstructive sleep apnoea in the short term Montelukast potentially efficacious in children with non-severe obstructive sleep apnoea in the short term | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Montelukast potentially efficacious in children with non-severe obstructive sleep apnoea in the short term Article Text Therapeutics Randomised

2013 Evidence-Based Medicine

9. Oral montelukast in acute asthma exacerbations: a randomised, double-blind, placebo-controlled trial Full Text available with Trip Pro

Oral montelukast in acute asthma exacerbations: a randomised, double-blind, placebo-controlled trial Although leukotriene receptor antagonists have an established role in the management of patients with chronic asthma, their efficacy in an acute asthma exacerbation is not fully known.87 adults with acute asthma requiring hospitalisation were randomly assigned to receive either montelukast 10 mg or placebo on admission and every evening thereafter for 4 weeks (when they were reviewed (...) as outpatients). All patients were admitted under the care of a consultant chest physician and received full care for acute asthma according to the British Thoracic Society guidelines. The primary end point was the difference in peak expiratory flow (PEF) between active and placebo treatment the morning following admission.Primary end point data were analysed for 73 patients. At study entry, patients who received montelukast (n=37) had a mean (±SD) PEF of 227.6 (±56.9) l/min (47.6% predicted) and those who

2011 EvidenceUpdates Controlled trial quality: predicted high

10. Effect of addition of single dose of oral montelukast to standard treatment in acute moderate to severe asthma in children between 5 and 15 years of age: a randomised, double-blind, placebo controlled trial Full Text available with Trip Pro

Effect of addition of single dose of oral montelukast to standard treatment in acute moderate to severe asthma in children between 5 and 15 years of age: a randomised, double-blind, placebo controlled trial To study the effect of the addition of a single dose of oral montelukast to standard therapy in acute moderate to severe asthma.Double-blind randomised controlled trial. Setting Emergency room/outpatient paediatric services of a tertiary care hospital.Children aged 5-15 years (without prior (...) use of montelukast) with acute moderate to severe asthma exacerbation, as defined using Modified Pulmonary Index Score (MPIS) > or =9, were enrolled.Children received montelukast (5-12 years: 5 mg and >12 years: 10 mg) or placebo orally in addition to the standard therapy. MPIS and forced expiratory volume in 1 second (FEV(1)) were recorded before administering study medication and thereafter, hourly for 4 hours.The primary outcome was decrease in MPIS to less than 9 at the end of 4 hours.117

2010 EvidenceUpdates Controlled trial quality: predicted high

11. Can montelukast shorten prednisolone therapy in children with mild to moderate acute asthma? A randomized controlled trial (Abstract)

Can montelukast shorten prednisolone therapy in children with mild to moderate acute asthma? A randomized controlled trial To examine whether outpatient post-stabilization therapy with montelukast produces more treatment failures than prednisolone.In this randomized, double-blind, double-dummy non-inferiority trial, 130 children 2 to 17 years of age with mild to moderate acute asthma stabilized with prednisolone in the emergency department received 5 daily treatments with either prednisolone (...) or montelukast after discharge. The primary outcome was treatment failure within 8 days (ie, an asthma-related unscheduled visit, hospitalization, or additional systemic corticosteroids).The rates of treatment failure were 7.9% in the prednisolone group and 22.4% in the montelukast group (95% CI, 26.5%-2.4%). Treatment was more likely to fail in younger patients (odds ratio, 4.9). In the montelukast group, more patients received additional pharmacotherapy than in patients receiving prednisolone (23.9% versus

2010 EvidenceUpdates Controlled trial quality: predicted high

12. Economic evaluation of quality-of-life improvement with second-generation antihistamines and montelukast in patients with allergic rhinitis

Economic evaluation of quality-of-life improvement with second-generation antihistamines and montelukast in patients with allergic rhinitis Economic evaluation of quality-of-life improvement with second-generation antihistamines and montelukast in patients with allergic rhinitis Economic evaluation of quality-of-life improvement with second-generation antihistamines and montelukast in patients with allergic rhinitis Saverno KR, Seal B, Goodman MJ, Meyer K Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of several second-generation antihistamines (levocetirizine, desloratadine, and fexofenadine) and montelukast for uncomplicated allergic rhinitis, focusing on improvements in quality

2009 NHS Economic Evaluation Database.

13. Once daily oral controller therapy with low dose theophylline or montelukast was not effective in poorly controlled asthma

Once daily oral controller therapy with low dose theophylline or montelukast was not effective in poorly controlled asthma Once daily oral controller therapy with low dose theophylline or montelukast was not effective in poorly controlled asthma | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Once daily oral controller therapy with low dose theophylline or montelukast was not effective in poorly controlled asthma Article Text

2008 Evidence-Based Medicine

14. Pretreatment with Albuterol versus Montelukast for Exercise-Induced Bronchospasm in Children (Abstract)

Pretreatment with Albuterol versus Montelukast for Exercise-Induced Bronchospasm in Children To compare pretreatment with albuterol versus montelukast added to the current asthma regimen for protection against exercise-induced bronchospasm in children with mild-to-moderate asthma, and to determine whether cysteinyl leukotriene (Cys-LT) concentrations measured in the exhaled breath condensate correlated with response to montelukast.Prospective, randomized, double-blind, double-dummy, crossover (...) study.Asthma clinic at a university-affiliated medical center.Eleven children aged 7-17 years with physician-diagnosed mild-to-moderate asthma for at least 6 months and with self-reported exercise-induced bronchospasm (defined as > or = 15% decrease in forced expiratory volume in 1 sec [FEV(1)] at screening and baseline visit).Patients were randomly assigned to receive 3-7 days of oral montelukast 5-10 mg/day or 2 puffs of an albuterol metered-dose inhaler just before an exercise challenge and then were

2008 EvidenceUpdates Controlled trial quality: predicted high

15. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review

Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review Joos S, Miksch A, Szecsenyi J, Wieseler B, Grouven U, Kaiser T, Schneider A CRD summary The authors concluded that adding montelukast (...) to inhaled corticosteroids (ICS) improved control of mild to moderate asthma, and that salmeterol was at least as effective as montelukast as an add-on therapy, but that montelukast may be safer long term. These conclusions may require some caution in interpretation due to the scarcity of good quality data and heterogeneity between the studies. Authors' objectives To evaluate the medium to long-term use of montelukast as add-on therapy to inhaled corticosteroids (ICS) in adolescents and adults

2008 DARE.

16. Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs

Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs O'Connor R D (...) ) and salmeterol (50 microg) administered twice daily from a single discus (FP-S); fluticasone propionate (FP; 100 microg); and montelukast (MO; 10 mg). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients aged 15 years or older with a diagnosis of asthma, as defined by the American Thoracic Society, for at least 6 months. Patients were required to demonstrate a pre-dose forced expiratory volume in one second (FEV1) of 50

2004 NHS Economic Evaluation Database.

17. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma

Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma O'Connor R D, Nelson H, Borker R, Emmett A, Jhingran P (...) administered via a single Diskus inhaler device twice daily. The other was an alternative strategy consisting of FP 100 microg twice daily via a Diskus inhaler plus oral montelukast (MON) 10 mg once daily. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients aged more than 15 years who had had asthma for at least 6 months and had been taking low-to-moderate doses of an ICS for at least 30 days before screening. At the time

2004 NHS Economic Evaluation Database.

18. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. Full Text available with Trip Pro

Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. To assess the effect of montelukast versus salmeterol added to inhaled fluticasone propionate on asthma exacerbation in patients whose symptoms are inadequately controlled with fluticasone alone. Design and setting A 52 week, two period, double blind, multicentre trial during which patients whose symptoms remained (...) uncontrolled by inhaled corticosteroids were randomised to add montelukast or salmeterol.Patients (15-72 years; n = 1490) had a clinical history of chronic asthma for > or = 1 year, a baseline forced expiratory volume in one second (FEV1) value 50-90% predicted, and a beta agonist improvement of > or = 12% in FEV1.The primary end point was the percentage of patients with at least one asthma exacerbation.20.1% of the patients in the group receiving montelukast and fluticasone had an asthma exacerbation

2003 BMJ Controlled trial quality: predicted high

19. A clinical review of montelukast in the treatment of seasonal allergic rhinitis

A clinical review of montelukast in the treatment of seasonal allergic rhinitis A clinical review of montelukast in the treatment of seasonal allergic rhinitis A clinical review of montelukast in the treatment of seasonal allergic rhinitis Gonyeau M J, Partisano A M CRD summary This review aimed to compare the efficacy of montelokast with current therapies for seasonal allergic rhinitis. The authors concluded that there was no evidence to support the use of montelokast (alone or in combination (...) with antihistamines) over intranasal corticosteroids. Limitations in the review methods and the reporting of included studies mean that these conclusions should be viewed with caution. Authors' objectives To assess the efficacy of montelukast in comparison with current therapies for seasonal allergic rhinitis. Searching MEDLINE and EMBASE were searched (1990 to week 8, 2003); the search terms were reported. Only studies published in the English language were included. Study selection Study designs of evaluations

2003 DARE.

20. Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs

Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs Stempel D A, O'Donnell J C, Meyer J W Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two alternative treatments for patients with moderate persistent asthma were examined. The treatments were inhaled corticosteroids (ICSs) used concurrently with salmeterol (ICS+SAL) or montelukast (ICS+MON). A third comparator, inhaled fluticasone propionate plus SAL (FP+SAL), was also considered. Type of intervention Treatment. Economic study

2002 NHS Economic Evaluation Database.